Capacity Expansion & Simplification of Supply chains for Viral Vector manufacture in the UK

Cell and gene therapy products are changing the lives of patients receiving treatment as part of early stage clinical trials. There is a clear need for a flexible rapid approach to the production of viral vector material to support both clinical trials and in-market supply for these innovative Gene Therapy products in order to rapidly treat patients. This joint project between Cobra Biologics and Symbiosis Pharmaceutical Services aims give the UK world leading capabilities for clinical and commercial production of gene therapy viral vectors . The project will support a larger investment to enhance in the production capabilities of both companies, streamlining and de-risking the manufacturing the viral vector products through operational and commercial alignment. The resulting simplified and enhanced supply chain offering will support existing and new customers’ clinical and commercial ambitions, leading to more innovative Gene Therapy medicines reaching patients. The outcome will be to establish the partner companies, and the UK, as internationally recognised centres of excellence in the field and establish commercial viral vector manufacturing capabilities within the UK.